Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KOD vs OTLK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OTLK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–4 Matrix Metrics)

OTLK Overall Winner 6-Pillar Tally: KOD 2 – 3 OTLK (1 Tie) Matrix Metrics: KOD 4 – 5 OTLK

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Kodiak Sciences Inc (KOD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). KOD carries a Unified Composite Score of 37.9/100 (SELL) at $103.51 (N/M Forward P/E, 0.0% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin).

  • Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. KOD 37.9/100 SELL) and 1.47β · 79% Vol risk profile, whereas KOD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: KOD trades in a Markup technical trend (SURGE options phase, RSI 58.3); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KOD vs OTLK
KOD NASDAQ
Kodiak Sciences Inc Common Stock
Biological Products, (No Disgnostic Substances)
$103.51
-6.91% 1D
Market Cap $6.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.18β · 69% Vol
Unified Composite Score
37.9 / 100 SELL
Tech 8.0 Fund 37.0 Flow 70.0 Mom 16.7
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (43.2% over 20 days), RSI 58
RSI-14: 58.3 · SMA20: $98.20 · SMA50: $78.07
OTLK NASDAQ Head-to-Head Winner
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
TTM Revenue N/A
Forward P/E 2.9x
Beta / 30D Vol 1.47β · 79% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.48 · SMA50: $0.56

6-Pillar Scorecard Institutional Category Breakdown (KOD 2 – 3 OTLK)

Columns: Metric · KOD · OTLK
1. Valuation Multiples OTLK
Forward P/E N/M 2.9x
Trailing P/E N/M 2.9x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale KOD
Revenue Growth (YoY) +0.0% -99.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $6.8B $107.1M
3. Profitability & Quality OTLK
Gross Margin N/A N/A
Operating Margin 0.0% 4781.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -368.4% -3.6%
4. Balance Sheet & Cash Flow KOD
Cash Generation (TTM) -$160M -$56M
Cash Flow Margin N/A N/A
Net Cash / Leverage $73M Net Cash $7.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OTLK
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 82.8% (3rd %ile) 181.3% (55th %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 0.26x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KOD (4) vs OTLK (5)
Institutional Metric KOD OTLK Criterion Row Edge
Market Capitalization
Scale
$6.8B $107.1M Larger Scale KOD
Trailing P/E Ratio
Valuation
N/M 2.9x Lower Multiple OTLK
Forward P/E Ratio
Valuation
N/M 2.9x Lower Multiple OTLK
Revenue Growth (YoY)
Growth
+0.0% -99.4% Higher Growth KOD
Operating Margin (TTM)
Profitability
0.0% 4781.8% Higher Margin OTLK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-368.4% -3.6% Higher ROE OTLK
52-Week Range Position
Momentum
90% ($18–$113) 10% ($0–$3) Stronger Trend KOD
Beta / 30D Volatility
Risk Regime
-0.18β · 69% Vol 1.47β · 79% Vol Lower Realized Risk KOD
Unified Institutional Score
Composite Signal
37.9 / 100 (SELL) 48.6 / 100 (HOLD) Higher Composite OTLK
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($73M Net Cash) -$56M ($7.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KOD +39.53 pp
KOD: +20.71% · OTLK: -18.82%
3M Horizon KOD +198.03 pp
KOD: +154.64% · OTLK: -43.39%
6M Horizon KOD +122.66 pp
KOD: +195.57% · OTLK: +72.91%
1Y Horizon KOD +521.58 pp
KOD: +448.54% · OTLK: -73.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KOD vs OTLK. Trailing 12-month operating profitability (KOD 0.0% vs OTLK 4781.8%) and valuation multiples (KOD N/M vs OTLK 2.9x Forward P/E) are benchmarked directly in Pillar 4 below.

KOD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-368.4% · N/M
OTLK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin4781.8%
ROE / Fwd P/E-3.6% · 2.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KOD SURGE
5d in phase · OBV NEUTRAL
Current IV 82.8%
IV Percentile 3rd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KOD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OTLK BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 181.3%
IV Percentile 55th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OTLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KOD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OTLK Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KOD vs OTLK Key Questions & Quantitative Answers

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Kodiak Sciences Inc (KOD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). KOD carries a Unified Composite Score of 37.9/100 (SELL) at $103.51 (N/M Forward P/E, 0.0% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin). Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. KOD 37.9/100 SELL) and 1.47β · 79% Vol risk profile, whereas KOD leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KOD trades in a Markup technical trend (SURGE options phase, RSI 58.3); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KOD leads the Growth & Scale pillar: KOD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OTLK at -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin). On trailing 12-month operating scale, KOD generates N/A in USD-normalized revenue versus N/A for OTLK. In operating R&D and SG&A reinvestment, KOD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OTLK.

OTLK screens cheaper on headline valuation multiples. KOD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KOD (-368.4% ROE) versus OTLK (-3.6% ROE) capital efficiency.

In options market volatility and institutional positioning, KOD carries 82.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (-0.18β · 69% Vol realized risk). By comparison, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.